Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reports that it has repurchased 170,000 ordinary shares of 31¼ pence each on 25 November 2025 through BNP Paribas SA as part of its existing share buyback programme. The shares were acquired at prices between 1,778.00p and 1,807.00p, with a volume-weighted average price of 1,789.59p per share, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 10,478,000 ordinary shares under this programme. After the latest transaction, the company holds 235,942,844 ordinary shares in treasury and has 4,079,489,083 ordinary shares in issue excluding treasury shares.
The total number of voting rights in GSK is 4,079,489,083, and the percentage of voting rights attributable to treasury shares is 5.78 per cent. Shareholders can use this voting rights figure when assessing whether they must notify their holdings under UK disclosure rules.
GSK plc reports that it repurchased 170,000 ordinary shares on 24 November 2025 through BNP Paribas SA as part of its existing share buyback programme. The shares, with a volume‑weighted average price of 1,784.93p and a price range between 1,775.50p and 1,793.50p, will be held as treasury shares.
Since 30 September 2025, GSK has bought 10,308,000 ordinary shares under this programme. After this latest transaction, it holds 235,772,844 ordinary shares in treasury and has 4,079,659,083 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,079,659,083, and the percentage of voting rights attributable to treasury shares is 5.78 per cent.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 180,000 ordinary shares of 31¼ pence each on 21 November 2025 as part of its existing share buyback programme. The shares were bought at prices between 1,753.00p and 1,783.00p, with a volume‑weighted average price of 1,766.33p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 10,138,000 ordinary shares under this programme. After this latest transaction, it holds 235,602,844 shares in treasury and has 4,079,829,083 ordinary shares in issue, which is also the total number of voting rights. GSK states that the voting rights represented by treasury shares are 5.77%.
GSK plc reports that it has repurchased 360,000 of its ordinary shares of 31¼ pence each on 20 November 2025, acting through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,755.00p and 1,783.00p per share, with a volume‑weighted average price of 1,766.45p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 9,958,000 ordinary shares under this programme. After the latest transaction, the company holds 235,422,844 shares in treasury and has 4,080,008,266 ordinary shares in issue, which is also the total number of voting rights. GSK confirms that treasury shares now represent 5.77% of its voting rights.
GSK plc reports that, under its existing share buyback programme, it repurchased 243,000 ordinary shares of 31¼ pence each on 19 November 2025 through BNP Paribas SA. The shares were bought at prices between 1,772.50p and 1,787.00p per share, with a volume‑weighted average price of 1,778.18p, and will be held as treasury shares.
Since 30 September 2025, GSK has repurchased 9,598,000 ordinary shares under this programme. After the latest transaction, GSK holds 235,062,844 shares in treasury and has 4,080,368,266 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by treasury shares is disclosed as 5.76%, helping shareholders calculate any notification thresholds under UK disclosure rules.
GSK plc reported that on 18 November 2025 it transferred 22,000,000 ordinary shares held in treasury to the GlaxoSmithKline Employee Trust, a Jersey resident trust. These shares will be used to satisfy awards under the company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The trustee paid £17.995 per share, funded by a loan from GlaxoSmithKline Services Unlimited.
After the transfer, GSK holds 234,819,844 ordinary shares in treasury and has 4,080,611,266 ordinary shares in issue, excluding treasury shares. The total number of voting rights is 4,080,611,266, and the percentage of voting rights attributable to treasury shares is 5.75%, which is relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that, under its existing share buyback programme, it repurchased 185,000 ordinary shares on 18 November 2025 through BNP Paribas SA. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,771.00p and 1,803.00p, with a volume-weighted average price of 1,780.45p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,355,000 ordinary shares under this programme. After this latest transaction, the company holds 234,819,844 shares in treasury and has 4,080,611,266 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,080,611,266, and the percentage of voting rights attributable to treasury shares is confirmed as 5.75 per cent.
GSK plc reported routine share dealings by senior personnel involving American Depositary Shares (ADSs). On 2025-11-14, Non-Executive Director Dr Hal Barron acquired approximately 2,732.837 notional ADSs in his GSK Executive Supplemental Savings Plan account and 69 ADSs in his GSK 401(k) plan account, both through the reinvestment of dividends at a price of $47.1800 per ADS. On the same date, James Ford, SVP and Group General Counsel, acquired 50.851 notional ADSs in his Executive Supplemental Savings Plan account, also via dividend reinvestment at $47.1800 per ADS. All transactions took place on the New York Stock Exchange.
GSK plc reports that on 17 November 2025 it repurchased 170,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing buyback programme. The shares were bought at prices between 1,781.00p and 1,800.50p per share, with a volume-weighted average price of 1,789.39p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,170,000 ordinary shares under this programme. After this transaction, it holds 256,634,844 shares in treasury and has 4,058,796,266 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by treasury shares is stated as 6.32%.
FAQ
What is the current stock price of GSK PLC (GLAXF)?
